NasdaqGS:TEMLife Sciences
Tempus AI (TEM) Logs First Non-GAAP Profit And Bullish 2025 Outlook Is The Thesis Evolving?
Earlier this month, Tempus AI reported a non-GAAP profit for Q3 2025 as genomics testing and data services gained momentum, while management outlined plans for additional FDA submissions to support higher average selling prices and improved unit economics.
The company also projected sharply higher 2025 revenue with positive adjusted EBITDA for the full year, suggesting that its growing testing footprint and data platform are beginning to scale operationally.
We’ll now explore how Tempus AI’s...